CYP2D6*10 alleles do not determine plasma fluvoxamine concentration/dose ratio in Japanese subjects

被引：24

作者：

Ohara, K ^{[1
]}

Tanabu, S ^{[1
]}

Ishibashi, K ^{[1
]}

Ikemoto, K ^{[1
]}

Yoshida, K ^{[1
]}

Shibuya, H ^{[1
]}

机构：

[1] Natl Minami Hanamaki Hosp, Clin Res Inst, Hanamaki 0250033, Japan

来源：

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY | 2003年 / 58卷 / 10期

关键词：

fluvoxamine; CYP2D6; *10 allele;

D O I：

10.1007/s00228-002-0529-3

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Objective: The purpose of the present study was to investigate whether plasma fluvoxamine (FV) concentration is associated with CYP2D6*10 allele polymorphisms. Methods: Subjects were 46 Japanese patients (21 males) carrying neither *3, *4 nor *5 alleles and treated orally using FV. Venous blood was obtained from each patient for determination of FV concentration/dose (C/D) ratio (plasma concentration of FV divided by daily dose of FV per body weight) and CYP2136 genotyping. Results: No significant differences in FV C/D ratio were found between subjects with no (n=13), one (n=18) or two (n=15) *10 alleles. Conclusion: Our results indicate that CYP2D6*10 genotypes do not exert significant effects on FV C/D ratio. As CYP2136 genotypes differ with ethnic background, further studies should be conducted in different populations.

引用

页码：659 / 661

页数：3

共 20 条

[1] Identification of novel polymorphisms in the 5′ flanking region of CYP1A2, characterization of interethnic variability, and investigation of their functional significance [J].

Aitchison, KJ ;

Gonzalez, FJ ;

Quattrochi, LC ;

Sapone, A ;

Zhao, JH ;

Zaher, H ;

Elizondo, G ;

Bryant, C ;

Munro, J ;

Collier, DA ;

Makoff, AJ ;

Kerwin, RW .

PHARMACOGENETICS, 2000, 10 (08) :695-704

[2] CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants [J].

Bradford, LD .

PHARMACOGENOMICS, 2002, 3 (02) :229-243

[3] Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity [J].

Carrillo, JA ;

Dahl, ML ;

Svensson, JO ;

Alm, C ;

Rodriguez, I ;

Bertilsson, L .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 60 (02) :183-190

[4] INTERPRETATION OF A SIMPLE PCR ANALYSIS OF THE CYP2D6(A) AND CYP2DG(B) NULL ALLELES ASSOCIATED WITH THE DEBRISOQUINE SPARTEINE GENETIC-POLYMORPHISM [J].

DOUGLAS, AM ;

ATCHISON, BA ;

SOMOGYI, AA ;

DRUMMER, OH .

PHARMACOGENETICS, 1994, 4 (03) :154-158

[5] GENOTYPING OF POOR METABOLIZERS OF DEBRISOQUINE BY ALLELE-SPECIFIC PCR AMPLIFICATION [J].

HEIM, M ;

MEYER, UA .

LANCET, 1990, 336 (8714) :529-532

[6] Unravelling the functional genomics of the human CYP2D6 gene locus [J].

Ingelman-Sundberg, M ;

Evans, WE .

PHARMACOGENETICS, 2001, 11 (07) :553-554

[7]

JOHANSSON I, 1994, MOL PHARMACOL, V46, P452

[8] Interethnic differences in drug metabolism: Influence of genetic and environmental factors on debrisoquine hydroxylation phenotype [J].

Llerena, A ;

Cobaleda, J ;

Martinez, C ;

Benitez, J .

EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 1996, 21 (02) :129-138

[9]

MCELROY S, 2000, AAPS PHARMSCI, V2

[10] FLUVOXAMINE - AN OVERVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND REVIEW OF ITS THERAPEUTIC POTENTIAL IN NON-DEPRESSIVE DISORDERS [J].

PALMER, KJ ;

BENFIELD, P .

CNS DRUGS, 1994, 1 (01) :57-87

← 1 2 →